James Mallen, DO
Pulmonary Disease · West Des Moines, IANPI 1720372782
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (38.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Intuitive Surgical at 52.6% of the total. Reporting peaked in 2023 at $7,042 and has fallen 98.0% since, to $138 in 2025. Among pulmonary disease clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $276.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Pinnacle Biologics, Inc$6K
- Veran Medical Technologies, Inc.$986
- Olympus America Inc.$108
- Johnson & Johnson$95
- Boehringer Ingelheim$55
- plus $85 from 2 others
What the payments were for
- Speaking & faculty fees$3,70023%
- Travel & lodging$4,19027%
- Food & beverage$1,80311%
- Education$6,07139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 23 | $8,287 |
| Pinnacle Biologics, Inc | 21 | $6,149 |
| Veran Medical Technologies, Inc. | 6 | $986 |
| Olympus America Inc. | 1 | $108 |
| Johnson & Johnson | 1 | $95 |
| Boehringer Ingelheim | 2 | $55 |
| KARL Storz Endoscopy-america | 1 | $47 |
| Insmed, Inc. | 2 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Photofrin$5,473
- Da Vinci Surgical System$4,855
- ION$3,000
- Spin$732
- Spiration Valve System$108
How this compares
$15,764 in reported general payments places this provider in the 90th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 440 | $293,646 |
| OfevNintedanib Esylate | 15 | $198,218 |
| Orenitram ErTreprostinil Diolamine | 28 | $193,860 |
| Breo ElliptaFluticasone/Vilanterol | 381 | $167,859 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 166 | $94,009 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 142 | $74,265 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $55,376 |
| Incruse ElliptaUmeclidinium Bromide | 118 | $54,316 |
| Ambrisentan | 13 | $35,561 |
| Spiriva HandihalerTiotropium Bromide | 45 | $31,896 |
| SymbicortBudesonide/Formoterol Fumarate | 122 | $30,278 |
| Arnuity ElliptaFluticasone Furoate | 81 | $18,122 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $12,897 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $11,338 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $55 | $296,334199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in West Des Moines
- Dustin McCannWest Des Moines$67K
- Matthew TrumpWest Des Moines$41K
- Samantha Danielson-JonesWest Des Moines$11K
- Ryan BrimeyerWest Des Moines$9K
- Amerlon EnriquezWest Des Moines$7K
- Daniel DodgeWest Des Moines$6K
- Ryan MertensWest Des Moines$6K
- John ScottWest Des Moines$3K
- Katrina GuestWest Des Moines$1K
- Gregory HicklinWest Des Moines$422
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.